Kyle J. Seamon

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

Matthew Holderfield, Bianca J. Lee, Jingjing Jiang et al. · Nature · 2024 · 318 citations · Full text

Medicine, Oncology, Pharmacology +16

Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers

Jingjing Jiang, Lingyan Jiang, Benjamin J. Maldonato et al. · Cancer Discovery · 2024 · 281 citations · Full text

Medicine, Oncology, Pharmacology +17

Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS

Christopher J. Schulze, Kyle J. Seamon, Yulei Zhao et al. · Science · 2023 · 232 citations · Full text

Medicine, Medicinal Chemistry, Oncology +17

SAMHD1 is a single-stranded nucleic acid binding protein with no active site-associated nuclease activity

Kyle J. Seamon, Zhiqiang Sun, Luda S. Shlyakhtenko et al. · Nucleic Acids Research · 2015 · 129 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +15

GTP activator and dNTP substrates of HIV-1 restriction factor SAMHD1 generate a long-lived activated state

Erik C Hansen, Kyle J. Seamon, Shannen L. Cravens et al. · Proceedings of the National Academy of Sciences · 2014 · 103 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +9